{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:59:55Z","timestamp":1778853595471,"version":"3.51.4"},"reference-count":45,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T00:00:00Z","timestamp":1313539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated whether variants in sex steroid hormone metabolism genes modify the effect of hormone therapy (HT) on endometrial cancer risk in postmenopausal non\u2010Hispanic white women. A nested case\u2013control study was conducted within the California Teachers Study (CTS). We genotyped htSNPs in six genes involved in the hormone metabolism in 286 endometrial cancer cases and 488 controls. Odds ratio (OR) and 95% confidence interval (CI) were estimated for each haplotype using unconditional logistic regression, adjusting for age. The strongest interaction was observed between duration of estrogen therapy (ET) use and haplotype 1A in <jats:italic>CYP11A1<\/jats:italic> (<jats:italic>p<\/jats:italic><jats:sub>interaction<\/jats:sub> = 0.0027; <jats:italic>p<\/jats:italic><jats:sub>interaction<\/jats:sub> = 0.010 after correcting for multiple testing within each gene). The OR for endometrial cancer per copy of haplotype 1A was 2.00 (95% CI: 1.05\u20133.96) for long\u2010term ET users and 0.90 (95% CI: 0.69\u20131.18) for never users. The most significant interaction with estrogen\u2010progestin therapy (EPT) was found for two haplotypes on <jats:italic>CYP19A1<\/jats:italic> and EPT use (haplotype 4A, <jats:italic>p<\/jats:italic><jats:sub>interaction<\/jats:sub> = 0.024 and haplotype 3B, <jats:italic>p<\/jats:italic><jats:sub>interaction<\/jats:sub> = 0.043). However, neither this interaction, nor the ET or EPT interactions for any other genes, was statistically significant after correction for multiple testing. Variations in <jats:italic>CYP11A1<\/jats:italic> may modify the effect of ET use on risk of postmenopausal endometrial cancer; however, larger studies are needed to explore these findings further.<\/jats:p>","DOI":"10.1002\/ijc.26163","type":"journal-article","created":{"date-parts":[[2011,5,4]],"date-time":"2011-05-04T17:40:56Z","timestamp":1304530856000},"page":"1629-1638","source":"Crossref","is-referenced-by-count":6,"title":["Variations in sex hormone metabolism genes, postmenopausal hormone therapy and risk of endometrial cancer"],"prefix":"10.1002","volume":"130","author":[{"given":"Pedram","family":"Razavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunjung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Van Den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela L.","family":"Horn\u2010Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giske","family":"Ursin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,8,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20006"},{"key":"e_1_2_6_3_2","first-page":"265","article-title":"Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative. Group","volume":"81","author":"Brinton LA","year":"1993","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0029-7844(94)00383-O"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.15.1110"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.13.1131"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07365-5"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023066304473"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(99)00192-4"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-05-0111"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-0712"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1019552126105"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddg294"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1101"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4123"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000071807"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:CACO.0000036170.28502.5f"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1069424"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/genetics\/50.4.757"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/genetics\/49.1.49","article-title":"The interaction of selection and linkage. I. General considerations heterotic models","volume":"49","author":"Lewontin RC","year":"1964","journal-title":"Genetics"},{"key":"e_1_2_6_21_2","first-page":"921","article-title":"Maximum\u2010likelihood estimation of molecular haplotype frequencies in a diploid population","volume":"12","author":"Excoffier L","year":"1995","journal-title":"Mol Biol Evol"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.2307\/3001775"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg563"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/12.12.2641"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/6.3.397"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031640"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(99)00628-7"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1158\/1055-9965.709.13.5","article-title":"Population\u2010based case\u2010control study of CYP11A gene polymorphism and breast cancer risk","volume":"13","author":"Zheng W","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20070"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-008-9160-7"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001012"},{"key":"e_1_2_6_32_2","first-page":"3955","article-title":"A polymorphism in CYP17 and endometrial cancer risk","volume":"61","author":"Haiman CA","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_33_2","first-page":"848","article-title":"Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype","volume":"61","author":"McKean\u2010Cowdin R","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2004.01.001"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00417.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-007-0454-8"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-08-0689"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwk015"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/22.2.347"},{"key":"e_1_2_6_40_2","first-page":"215","article-title":"No association between a single nucleotide polymorphism in CYP19 and breast cancer risk","volume":"11","author":"Haiman CA","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-03-0026"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004320000200"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21041"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2009.02185.x"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-03-0241"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.11.014"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.26163","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.26163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T03:57:46Z","timestamp":1697515066000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.26163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,17]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1002\/ijc.26163"],"URL":"https:\/\/doi.org\/10.1002\/ijc.26163","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,17]]}}}